Publications by authors named "D Joshua"
A 20-year evidence-based experience of the evolving medicine regulation in Zanzibar.
J Pharm Policy Pract
November 2024
Background: Access to medicine is crucial for the effective functioning of healthcare systems. A robust regulatory framework is necessary to ensure the safety, effectiveness, and availability. However, weak regulatory frameworks persist in many low- and middle-income countries, leasing to the circulation of falsified and substandard medicines as well as anti-competitive restrictions on registering poor-quality medicines, which poses a significant public health threat.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the effectiveness of smartphone applications for education and clinical decision support in neonatal emergency care, targeting the reduction of neonatal mortality in low- and middle-income countries.
- A systematic search revealed 20 studies about various apps, finding that most participants deemed them acceptable, and many reported improvements in knowledge and skills.
- The review underscores the potential of these applications to lower neonatal mortality rates but calls for more research to validate their effectiveness and address gaps in the literature.
Article Synopsis
- Among 85 patients analyzed, 35.3% received PCAB with additional agents, particularly bortezomib, but high rates of severe side effects like cytopenia and febrile neutropenia were observed.
- Some patients were able to successfully transition to CAR T-cell therapy, suggesting that PCAB may serve as a valuable bridge to newer treatments, warranting further study into its effectiveness.
Background And Purpose: Renal impairment (RI) confers adverse prognosis in myeloma; its reversal and avoidance of dialysis are crucial. We investigated whether serum free light chain (SFLC) measurements can predict renal outcome, to enable change in therapy to optimize prognosis and avoid dialysis.
Patients And Methods: We investigated 36 myeloma patients (17 newly diagnosed [ND]; 19 relapsed refractory [RR]; with median of 5 prior lines) with eGFR 15-40 ml/min treated with carfilzomib (Cfz)-dexamethasone to determine whether SFLC kinetics can predict renal outcomes, and assess efficacy and tolerability.